The Relationship Between Cisplatin‐related and Age‐related Hearing Loss During an Extended Follow‐up

Skalleberg, Jakob; Småstuen, Milada Cvancarova; Oldenburg, Jan; Osnes, Terje; Fosså, Sophie D.; Bunne, Marie

doi:10.1002/lary.28543

Cited by 11 publications

(12 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some cancers, such as testicular cancer (TC), are identi ed in young adulthood, thus the retention of cisplatin in the cochlea is especially troubling as these patients have upwards of 50 years of lifespan ahead of them. A 2018 study (Haugnes et al, 2018) found a signi cant effect of cisplatin-related hearing loss that exacerbated age-related hearing loss in TC survivors; however, in a con icting later study from this group (Skalleberg et al, 2020), age-related hearing loss appeared similar to cisplatin-related hearing loss, supporting the theory that cisplatin may not exacerbate age-related hearing loss. Regardless of the mechanism(s) of action of cisplatin-related hearing loss, there is increased concern for the potential longterm consequences of hearing loss that have been reported in the general population, including clinicallyrelevant decreases in communication and health-related quality of life (Carabellese et al, 1993;Chia et al, 2007;Dalton et al, 2003;Mulrow et al, 1990) Thus, hearing loss and tinnitus related to cisplatin-based chemotherapy are important to understand in cancer survivorship.…”

Section: Introductionmentioning

confidence: 95%

Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy

et al. 2023

View full text Add to dashboard Cite

PURPOSEOtotoxicity is a prominent side effect of cisplatin-based chemotherapy. There are few reports, however, estimating its prevalence in well-de ned cohorts and associated risk-factors. METHODSTesticular cancer (TC) survivors given rst-line cisplatin-based chemotherapy completed validated questionnaires. Descriptive statistics evaluated ototoxicity prevalence. We compared patients with and without tinnitus or hearing loss using Chi-square test, two-sided Fisher's Exact test, or two-sided Wilcoxon Rank Sum test. To evaluate ototoxicity risk factors, a backward selection logistic regression procedure was performed. RESULTSOf 145 TC survivors, 74% reported ototoxicity: 68%-tinnitus; 59% hearing loss; and 52% reported both. TC survivors with tinnitus were more likely to indicate hypercholesterolemia (P=0.008), and di culty hearing (P<.001). Tinnitus was also signi cantly related to age at survey-completion (OR=1.79; P=0.003) and cumulative cisplatin dose (OR=5.17; P<0.001). TC survivors with hearing loss were more likely to report diabetes (P=0.042), hypertension (P=0.007), hypercholesterolemia (P<0.001), and family-history of hearing loss (P=0.044). Risk factors for hearing loss included age at survey-completion (OR=1.57; P=0.036), hypercholesterolemia (OR=3.45; P=0.007), cumulative cisplatin dose (OR=1.94; P=0.049), and family history of hearing loss (OR=2.87; P=0.071). CONCLUSIONSOtotoxicity risk factors included age, cisplatin dose, cardiovascular risk factors, and family-history of hearing loss. Three of four TC survivors report some type of ototoxicity; thus, follow-up of cisplatintreated survivors should include routine assessment for ototoxicity with provision of indicated treatments.

show abstract

Section: Introductionmentioning

confidence: 95%

Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Therefore, monitoring of cochleotoxic effects of cisplatin is advised and implemented in clinical practice ( Brooks and Knight, 2017 ; Clemens et al, 2019 ; Sprouse and Gozdecki, 2019 ). Age- and sex-adjusted audiometry is also suggested in long-term follow-up of adult cancer survivors to minimize the effects of age-related hearing loss ( Skalleberg et al, 2020 ).…”

Section: Clinical Data Of Cisplatin Ototoxicitymentioning

confidence: 99%

Preferential Cochleotoxicity of Cisplatin

et al. 2021

View full text Add to dashboard Cite

Cisplatin-induced ototoxicity in humans is more predominant in the cochlea than in the vestibule. Neither definite nor substantial vestibular dysfunction after cisplatin treatment has been consistently reported in the current literature. Inner ear hair cells seem to have intrinsic characteristics that make them susceptible to direct exposure to cisplatin. The existing literature suggests, however, that cisplatin might have different patterns of drug trafficking across the blood-labyrinth-barrier, or different degrees of cisplatin uptake to the hair cells in the cochlear and vestibular compartments. This review proposes an explanation for the preferential cochleotoxicity of cisplatin based on current evidence as well as the anatomy and physiology of the inner ear. The endocochlear potential, generated by the stria vascularis, acting as the driving force for hair cell mechanoelectrical transduction might also augment cisplatin entry into cochlear hair cells. Better understanding of the stria vascularis might shed new light on cochleotoxic mechanisms and inform the development of otoprotective interventions to moderate cisplatin associated ototoxicity.

show abstract

“…Our findings show that for patients with self-reported HL after CBCT but normal audiometric findings (0.25 to 8 kHz), referral to an audiologist for additional testing and inclusion of EHFs should be encouraged. This is especially important in relatively young TCS, since they are less likely to experience the deficits in EHFs that accompany aging (Skalleberg et al 2020). To our knowledge, there are no follow-up guidelines for audiometric assessments in CBCT-treated adult-onset cancer survivors.…”

Section: Discussionmentioning

confidence: 99%

Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments

Ardeshir-Rouhani-Fard

Fosså

Huddart

et al. 2022

Ear &Amp; Hearing

View full text Add to dashboard Cite

Objectives: To provide new information on factors associated with discrepancies between patient-reported and audiometrically defined hearing loss (HL) in adult-onset cancer survivors after cisplatin-based chemotherapy (CBCT) and to comprehensively investigate risk factors associated with audiometrically defined HL.Design: A total of 1410 testicular cancer survivors (TCS) ≥6 months post-CBCT underwent comprehensive audiometric assessments (0.25 to 12 kHz) and completed questionnaires. HL severity was defined using American Speech-Language-Hearing Association criteria. Multivariable multinomial regression identified factors associated with discrepancies between patient-reported and audiometrically defined HL and multivariable ordinal regression evaluated factors associated with the latter.Results: Overall, 34.8% of TCS self-reported HL. Among TCS without tinnitus, those with audiometrically defined HL at only extended high frequencies (EHFs) (10 to 12 kHz) (17.8%) or at both EHFs and standard frequencies (0.25 to 8 kHz) (23.4%) were significantly more likely to self-report HL than those with no audiometrically defined HL (8.1%) [odds ratio (OR) = 2.48; 95% confidence interval (CI), 1.31 to 4.68; and OR = 3.49; 95% CI, 1.89 to 6.44, respectively]. Older age (OR = 1.09; 95% CI, 1.07 to 1.11, p < 0.0001), absence of prior noise exposure (OR = 1.40; 95% CI, 1.06 to 1.84, p = 0.02), mixed/conductive HL (OR = 2.01; 95% CI, 1.34 to 3.02, p = 0.0007), no hearing aid use (OR = 5.64; 95% CI, 1.84 to 17.32, p = 0.003), and lower education (OR = 2.12; 95% CI, 1.23 to 3.67, p = 0.007 for high school or less education versus postgraduate education) were associated with greater underestimation of audiometrically defined HL severity, while tinnitus was associated with greater overestimation (OR = 4.65; 95% CI, 2.64 to 8.20 for a little tinnitus, OR = 5.87; 95% CI, 2.65 to 13.04 for quite a bit tinnitus, and OR = 10.57; 95% CI, 4.91 to 22.79 for very much tinnitus p < 0.0001). Older age (OR = 1.13; 95% CI, 1.12 to 1.15, p < 0.0001), cumulative cisplatin dose (>300 mg/m 2, OR = 1.47; 95% CI, 1.21 to 1.80, p = 0.0001), and hypertension (OR = 1.80; 95% CI, 1.28 to 2.52, p = 0.0007) were associated with greater American Speech-Language-Hearing Associationdefined HL severity, whereas postgraduate education (OR = 0.58; 95% CI, 0.40 to 0.85, p = 0.005) was associated with less severe HL.Conclusions: Discrepancies between patient-reported and audiometrically defined HL after CBCT are due to several factors. For survivors who self-report HL but have normal audiometric findings at standard frequencies, referral to an audiologist for additional testing and inclusion of EHFs in audiometric assessments should be considered.

show abstract

The Relationship Between Cisplatin‐related and Age‐related Hearing Loss During an Extended Follow‐up

Cited by 11 publications

References 51 publications

Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy

Prevalence and risk factors for ototoxicity after cisplatin-based chemotherapy

Preferential Cochleotoxicity of Cisplatin

Ototoxicity After Cisplatin-Based Chemotherapy: Factors Associated With Discrepancies Between Patient-Reported Outcomes and Audiometric Assessments

Contact Info

Product

Resources

About